Search clinical trials for: E7080

Total 145 results

Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Solid Tumors

United States, China, Belgium, Australia, Italy, Korea, Republic of, Germany, Netherlands, Poland, Romania, Thailand
Eisai Pharmaceuticals India Pvt. Ltd

Completed

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Carcinoma, Hepatocellular

India
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Osteosarcoma

Korea, Republic of, New Zealand, Spain, United States, Sweden, Taiwan, Singapore, Hong Kong, United Kingdom, France, Belgium, Switzerland, Australia, Ireland, Canada, Israel, Italy, Austria, Czechia, Finland, Netherlands
Eisai Co., Ltd.

Completed

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Differentiated Thyroid Cancer (DTC)

China
Eisai Inc.

Terminated

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Thyroid Carcinoma, Anaplastic

Italy, United States, France, Australia, United Kingdom
Eisai Inc.

Completed

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

Healthy Volunteers

United States
Eisai Inc.

Completed

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

Healthy Volunteers

United States
Eisai Inc.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma (STELLAR)

Carcinoma, Hepatocellular

United States, Spain, United Kingdom, Australia, Sweden, Italy, Austria, Germany, Portugal, Russian Federation
Eisai Co., Ltd.
Merck Sharp & Dohme LLC

Completed

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Spain, France, Italy, Japan, Russian Federation, United Kingdom
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Tumors

Spain, United States, Norway
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

Renal Cell Carcinoma

China
Eisai Co., Ltd.
Merck Sharp & Dohme LLC

Completed

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Solid Tumors

Japan
Eisai Inc.

Terminated

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Carcinoma, Hepatocellular

United States
Eisai Inc.

Completed

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Tumors

United States
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Renal Cell Carcinoma

Spain, Canada, Portugal, Korea, Republic of, Taiwan, United States, Netherlands, United Kingdom, Czechia, Italy, Finland, Greece, Romania, Australia, Poland, Russian Federation
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Recurrent and Refractory Solid Tumors

United States, Canada
Eisai Limited
Merck Sharp & Dohme LLC

Completed

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Osteosarcoma | Tumors | Differentiated Thyroid Cancer (DTC) | Solid Malignant Tumors

Spain, Italy, United States, United Kingdom, France, Germany
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Thyroid Cancer

United States, Canada, Germany, Korea, Republic of, Spain, France, Australia, Belgium, Denmark, Israel, Italy, Poland, Romania, Russian Federation, Sweden, United Kingdom
Eisai Korea Inc.

Completed

Post-Marketing Surveillance of Lenvima in Korean Patients

Differentiated Thyroid Carcinoma (DTC)

Korea, Republic of
Eisai Co., Ltd.

Completed

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

Unresectable Hepatocellular Carcinoma (HCC)

China
Eisai Co., Ltd.

Completed

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Biliary Tract Cancer

Japan
M.D. Anderson Cancer Center
Eisai Inc.

Withdrawn

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Advanced Cancer | Malignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms... and other conditions
Hyogo Medical University
Merck Sharp & Dohme LLC

Not yet recruiting

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)

Malignant Pleural Mesothelioma

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Carcinoma, Renal Cell

Spain, United States, Australia, Canada, Chile, Colombia, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)-China Extension Study

Head and Neck Squamous Cell Carcinoma

China
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231)

Relapsed or Refractory Solid Tumors

United States, Argentina, Australia, Belgium, Croatia, Czechia, France, Guatemala, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Peru, Russian Federation, Serbia, South Africa, Spain, Sweden, Turkey
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Non-small Cell Lung Cancer

China, Israel, United States, Australia, Canada, Colombia, Estonia, France, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Taiwan, Turkey, Ukraine
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Carcinoma, Renal Cell

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Metastatic Adrenal Gland Pheochromocytoma | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Carcinoma, Renal Cell

United States, Australia, Canada, Chile, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (LEAP-015)

Advanced/Metastatic Gastroesophageal Adenocarcinoma

China, Japan, Poland, Hong Kong, Korea, Republic of, Canada, United States, Argentina, Australia, Belgium, Chile, Colombia, Costa Rica, France, Germany, Guatemala, Ireland, Israel, Italy, Russian Federation, Spain, Taiwan, Turkey, United...
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

Melanoma

Spain, United States, Australia, France, Israel, Italy, South Africa, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Neuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Advanced Carcinoid Tumor | Digestive System Neuroendocrine Neoplasm | Unresectable Carcinoid Tumor

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Advanced Melanoma

Canada, United States, Australia, Spain, Sweden
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Nonsquamous Non-small Cell Lung Cancer

United States, Argentina, Australia, Canada, Chile, China, France, Germany, Israel, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, United Kingdom
Humanity & Health Medical Group Limited
Beijing 302 Hospital; Kindai University Faculty of Medicine

Terminated

Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors

Hepatocellular Carcinoma

Hong Kong
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Carcinoma, Hepatocellular

Colombia, Israel, Taiwan, United States, Australia, Brazil, Chile, China, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Portugal, Puerto Rico, Spain, Thailand, Turke... and more
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Pathologic Stage... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

Rectal Cancer | Rectal Adenocarcinoma

United States
National Cancer Center Hospital East
Merck Sharp & Dohme LLC; Eisai Co., Ltd.

Completed

Lenvatinib and Pembrolizumab Simultaneous Combination Study (Lenva+Pembro)

Advanced Gastric Cancer

Japan
Eisai Inc.

Completed

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
RenJi Hospital

Unknown

Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma

Hepatocellular Carcinoma
Eisai Inc.

Completed

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Stage IV Melanoma | Unresectable Stage III

United States, United Kingdom, Australia, Germany
UMC Utrecht

Completed

A Randomized, Placebo-controlled, Double Blind Trial to Investigate Whether Vitamin K2 Can Influence Arterial Calcification in Patients With Type 2 Diabetes (Vitacal)

Diabetes Mellitus Type 2 | Arterial Calcification

Netherlands
Eisai Co., Ltd.

Completed

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

Japan, Korea, Republic of
Eisai Inc.
Quintiles, Inc.

Completed

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Non-Small Cell Lung Cancer

Belgium, Korea, Republic of, Italy, United States, Hungary, United Kingdom, Czechia
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Hepatic Impairment | Hepatic Function

United States
Eisai Inc.

Completed

A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers

Healthy Volunteers | P-glycoprotein

United States
Eisai Co., Ltd.

Completed

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Non-small-cell Lung Cancer

Japan

Search clinical trials for: E7080

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations